Art. -Nr.: HY-P1033

Copy Link Print Information

[Pyr1]-Apelin-13

(Synonyms: [pGlu1]-Apelin-13)

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.64%
CAS. Nr.: 217082-60-5
Formel: C₆₉H₁₀₈N₂₂O₁₆S
Molecular Weight:1533.80

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

[Pyr1]-Apelin-13 Chemical Structure

CAS. Nr.: 217082-60-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

[Pyr1]-Apelin-13 is a highly potent, selective endogenous apelin receptor (APJ) agonist.

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.42 nM Compound: 1, Pyr-apelin-13	Agonist activity at APJ receptor (unknown origin) expressed in CHO cells co-expressing with Calphaq16 assessed as calcium mobilization Agonist activity at APJ receptor (unknown origin) expressed in CHO cells co-expressing with Calphaq16 assessed as calcium mobilization	[PMID: 24755525]
CHO	EC₅₀	0.002 μM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHO cells co-expressing Galphaq16 assessed as increase in intracellular calcium mobilization measured at 1 sec intervals for 90 secs by calcium 5 dye based FLIPR assay Agonist activity at human APJ receptor stably expressed in CHO cells co-expressing Galphaq16 assessed as increase in intracellular calcium mobilization measured at 1 sec intervals for 90 secs by calcium 5 dye based FLIPR assay	[PMID: 31948845]
CHO	EC₅₀	0.0003 μM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay	[PMID: 31948845]
CHO	EC₅₀	0.3 nM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay Agonist activity at human APJ receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured after 30 mins by Eu-cAMP tracer based TR-FRET assay	[PMID: 31948845]
CHO-K1	EC₅₀	0.001 μM Compound: Pyr-Apelin-13	Agonist activity at human APJ receptor stably expressed in CHOK1 cells assessed as induction of beta-arrestin 2 recruitment incubated for 90 mins by PathHunter assay Agonist activity at human APJ receptor stably expressed in CHOK1 cells assessed as induction of beta-arrestin 2 recruitment incubated for 90 mins by PathHunter assay	[PMID: 31948845]
HEK293	EC₅₀	12.2 pM Compound: [pyr1]-apelin-13	Agonist activity at APJ receptor in HEK293 cells assessed as inhibition of forskolin-induced cAMP level incubated for 5 mins prior to forskolin challenge measured after 30 mins by TR-FRET assay Agonist activity at APJ receptor in HEK293 cells assessed as inhibition of forskolin-induced cAMP level incubated for 5 mins prior to forskolin challenge measured after 30 mins by TR-FRET assay	[PMID: 25241924]
HEK293	EC₅₀	0.84 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of Galphai1 subunit dissociation incubated for 5 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of Galphai1 subunit dissociation incubated for 5 mins by BRET assay	[PMID: 25668242]
HEK293	EC₅₀	1.4 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced intracellular cAMP production incubated for 30 mins by TR-FRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced intracellular cAMP production incubated for 30 mins by TR-FRET assay	[PMID: 25668242]
HEK293	EC₅₀	26 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-1 recruitment subunit dissociation incubated for 30 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-1 recruitment subunit dissociation incubated for 30 mins by BRET assay	[PMID: 25668242]
HEK293	EC₅₀	29 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-2 recruitment subunit dissociation incubated for 30 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of beta-arrestin-2 recruitment subunit dissociation incubated for 30 mins by BRET assay	[PMID: 25668242]
HEK293	EC₅₀	5.9 nM Compound: Ape13	Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of GalphaoA subunit dissociation incubated for 5 mins by BRET assay Agonist activity at human APJ receptor expressed in HEK293 cells assessed as induction of GalphaoA subunit dissociation incubated for 5 mins by BRET assay	[PMID: 25668242]
HEK293	IC₅₀	1.2 nM Compound: Ape13	Displacement of [125I]apelin-13[Glp65,Nle75,Tyr77] from YFP epitope-tagged human APJ receptor expressed in HEK293 cell membranes incubated for 1 hr by gamma counting method Displacement of [125I]apelin-13[Glp65,Nle75,Tyr77] from YFP epitope-tagged human APJ receptor expressed in HEK293 cell membranes incubated for 1 hr by gamma counting method	[PMID: 25668242]
HEK293	EC₅₀	1.1 nM Compound: Ape13	Activity at human APJ receptor expressed in HEK293 cells assessed as dissociation of Galphai1 from Gbetagamma subunit after 5 mins by BRET assay Activity at human APJ receptor expressed in HEK293 cells assessed as dissociation of Galphai1 from Gbetagamma subunit after 5 mins by BRET assay	[PMID: 29461833]
HEK293	EC₅₀	24 nM Compound: Ape13	Induction of human HA-tagged APJ receptor internalization expressed in HEK293 cells after 30 mins by ELISA Induction of human HA-tagged APJ receptor internalization expressed in HEK293 cells after 30 mins by ELISA	[PMID: 29461833]
HEK293	EC₅₀	60 nM Compound: Ape13	Activity at GFP10-tagged human APJ receptor expressed in HEK293 cells assessed as induction of RlucII-tagged beta-arrestin-2 recruitment after 30 mins by BRET assay Activity at GFP10-tagged human APJ receptor expressed in HEK293 cells assessed as induction of RlucII-tagged beta-arrestin-2 recruitment after 30 mins by BRET assay	[PMID: 29461833]
HEK293	EC₅₀	0.047 nM Compound: 1; (Pyr1)apelin-13	Agonist activity at human APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay Agonist activity at human APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay	[PMID: 31724863]
HEK293	EC₅₀	0.062 nM Compound: 1; (Pyr1)apelin-13	Agonist activity at rat APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay Agonist activity at rat APJ-R expressed in HEK293 cells assessed as inhibition of forskolin- stimulated cAMP accumulation incubated for 30 mins by HTRF assay	[PMID: 31724863]

In Vitro

[Pyr1]-apelin-13 encapsulation in lipoPEG particles (lipoPEG-PA13) results in sustained and extended drug release under physiological conditions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

[Pyr1]-apelin-13 nanocarriers in a mouse model of pressure-overload induced heart failure demonstrate a sustainable long-term effect of [Pyr1]-apelin-13 in preventing cardiac dysfunction^[1]. [Pyr1] apelin-13 (1, 5 μg) improves locomotor activity and reduces pain symptoms, cavity size and caspase-3 levels in rats. [Pyr1] apelin-13 (1, 5 μg) significantly increases thermal paw withdrawal latency. [Pyr1] apelin-13 in 5 μg dose also produces significant attenuation in paw withdrawal threshold compared to SCI animals from the second week post SCI^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 217082-60-5
Appearance Solid
Molecular Weight 1533.80
Formel C₆₉H₁₀₈N₂₂O₁₆S
Color White to off-white
Synonyms

[pGlu1]-Apelin-13
Sequence

{Glp}-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe
Sequence Shortening

{Glp}-RPRLSHKGPMPF
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (5)

All IFCell Proliferation/Viability AssayWB2D/3D Cell Culture and DifferentiationCell Migration/Invasion Assay

Sort by:

Journal Impact Factor

J Transl Med

Apelin-13 attenuates optic nerve damage in glaucomatous mice by regulating glucose metabolism. [Abstract]

2025 Feb 18;23(1):200. PMID: 39966959

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

The number of RGCs was significantly lesser in the PECE group than in the control group. Moreover, the number of surviving RGCs was significantly greater in the Apelin-13 (10 µg/eye) group than in the PECE group.

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

The ratios of p-PI3K/PI3K and p-Akt/Akt in the retina of the PECE group were decreased, while those in the Apelin-13 (10 µg/eye) group returned to normal.

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

Tube formation experiment. The mBMECs in matrix gels were treated with vehicle or Apln13 (100 ng/mL) in reduced growth media (2% FBS) or cultured in normal growth media (5% FBS) for 4 h. Representative images of tubular-like structures.

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Feb 18;23(1):200. [Abstract]

In vitro scratch assay in mBMEC cultures in reduced growth media (2% FBS) with vehicle or Apln13 treatment (100 ng/mL). Normal growth media (5% FBS) was used as a positive control. Scratch area closure was assessed after 0, 6, 12, 24, and 30 h.
Int Immunopharmacol

Apelin-13 alleviated ischemia reperfusion injury via KLF2/NF-κB signaling pathway after kidney transplantation. [Abstract]

2026 Jan 1;168(Pt 1):115802. PMID: 41223609
iScience

Single-cell transcriptomic analyses reveal angiogenic vascular responses to chronic cerebral hypoperfusion. [Abstract]

2026 Mar 11;29(4):115331. PMID: 41907427

[Pyr1]-Apelin-13 purchased from MedChemExpress. Usage Cited in: iScience. 2026 Mar 11;29(4):115331. [Abstract]

Proliferation analysis under different concentrations of Apln13 treatment (0, 10, 100, and 500 ng/mL) for 20 h.
SSRN

2026 Jun 17.
Research Square Print

2023 Jan 23.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 100 mg/mL (65.20 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.6520 mL

3.2599 mL

6.5198 mL

5 mM

0.1304 mL

0.6520 mL

1.3040 mL

10 mM

0.0652 mL

0.3260 mL

0.6520 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (65.20 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Serpooshan V, et al. [Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials. 2015 Jan;37:289-98. [Content Brief]

[2]. Hajimashhadi Z, et al. Chronic administration of [Pyr1] apelin-13 attenuates neuropathic pain after compression spinal cord injury in rats. Neuropeptides. 2017 Feb;61:15-22. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	0.6520 mL	3.2599 mL	6.5198 mL	16.2994 mL
	5 mM	0.1304 mL	0.6520 mL	1.3040 mL	3.2599 mL
	10 mM	0.0652 mL	0.3260 mL	0.6520 mL	1.6299 mL
	15 mM	0.0435 mL	0.2173 mL	0.4347 mL	1.0866 mL
	20 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8150 mL
	25 mM	0.0261 mL	0.1304 mL	0.2608 mL	0.6520 mL
	30 mM	0.0217 mL	0.1087 mL	0.2173 mL	0.5433 mL
	40 mM	0.0163 mL	0.0815 mL	0.1630 mL	0.4075 mL
	50 mM	0.0130 mL	0.0652 mL	0.1304 mL	0.3260 mL
	60 mM	0.0109 mL	0.0543 mL	0.1087 mL	0.2717 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

[Pyr1]-Apelin-13

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

[Pyr1]-Apelin-13

Peptide Library

Publications Citing Use of MedChemExpress (MCE) [Pyr1]-Apelin-13

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

[Pyr1]-Apelin-13

Peptide Library

Publications Citing Use of MedChemExpress (MCE) [Pyr1]-Apelin-13

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

[Pyr1]-Apelin-13 Related Classifications

HY-P1033 Related Classifications